SEC Form 4 · accession 0001209191-16-136838
HERON THERAPEUTICS, INC. /DE/ · HRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Rosen
Officer — President & CCO · Director
Period of report
Aug 10, 2016
Accepted (ET)
Aug 12, 2016 · 5:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818033
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 10, 2016 | M | 100,000 | $7.20 | A | 102,640 | D | |
| Common StockF2 | Aug 10, 2016 | S | 87,600 | $23.2148 | D | 15,040 | D | |
| Common StockF3 | Aug 10, 2016 | S | 12,400 | $23.8934 | D | 2,640 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F4 | $7.20 | Aug 10, 2016 | M | 100,000 | D | — | May 1, 2023 | Common Stock | 100,000 | 825,000 | D |
Explanation of responses
- F1The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed in 2015.
- F2The range of sales prices received was $22.78 to $23.77. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- F3The range of sales prices received was $23.78 to $24.00. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- F4At the date of filing, 444,532 shares of the options granted pursuant to the underlying awards were fully vested and exercisable.